Agenda Details

The 3rd Party Service Provider: Unavoidable Necessity or Powerful Partner?

Add to My Schedule

Thursday, May 30, 2024 09:15 AM - 10:15 AM

205-207

COGs & Business Models

Roundtable

Moderator(s)

Massimo Dominici, MD, University Hospital of Modena Reggio Emilia - Modena Policlinic, Italy

Panelists

Snehal Patel, Chief Technical Officer, Sana Biotechnology, USA
Farzin Farzaneh, Chief Scientific Officer, ViroCell, United Kingdom
Ramona Repaczki-Jones, MS, Executive Director, Cell Therapy Operations, Medical Affairs, Iovance, USA

The cost to build the supporting infrastructure and hire the team you need to fully support the development, manufacturing and testing of CGT products is not easily absorbed by most biotech companies, and even some big pharma. One might also argue that it shouldn’t be borne by those companies, that the funding they receive should go towards what they do best; research, early development and discovery, advocacy and education, and clinical management. Many other companies, namely service providers, are funded explicitly to provide that infrastructure and support as efficiently and expertly as possible, so it's logical to argue we should leave that job to them. How do we best divide those responsibilities and conquer the challenges involved to bring therapeutics to market faster?

Learning Objectives
1. How do you determine the right sourcing strategy for your product and/or organization?
2. What are the key characteristics of a strong partnership?
3. How do you handle unexpected changes or outcomes without damaging your relationship with your third-party provider?

Speakers/Moderators

Ramona Repaczki-Jones
Executive Director, Cell Therapy Operations
Iovance Biotherapeutics
Panelist

Massimo Dominici
Professor
Università di Modena e Reggio Emilia
Moderator

Farzin Farzaneh
CSO
ViroCell
Panelist

Snehal Patel
Chief Technical Officer
Sana Biotechnology
Panelist

Session Details